ES2973101T3 - Métodos para tratar proteinopatías - Google Patents

Métodos para tratar proteinopatías

Info

Publication number
ES2973101T3
ES2973101T3 ES16711088T ES16711088T ES2973101T3 ES 2973101 T3 ES2973101 T3 ES 2973101T3 ES 16711088 T ES16711088 T ES 16711088T ES 16711088 T ES16711088 T ES 16711088T ES 2973101 T3 ES2973101 T3 ES 2973101T3
Authority
ES
Spain
Prior art keywords
proteinopathies
treat
methods
treat proteinopathies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16711088T
Other languages
English (en)
Inventor
Seng Cheng
Lamya Shihabuddin
Sergio Sardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of ES2973101T3 publication Critical patent/ES2973101T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
ES16711088T 2015-03-10 2016-03-09 Métodos para tratar proteinopatías Active ES2973101T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131071P 2015-03-10 2015-03-10
PCT/US2016/021512 WO2016145046A1 (en) 2015-03-10 2016-03-09 Methods for treating proteinopathies

Publications (1)

Publication Number Publication Date
ES2973101T3 true ES2973101T3 (es) 2024-06-18

Family

ID=55587378

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16711088T Active ES2973101T3 (es) 2015-03-10 2016-03-09 Métodos para tratar proteinopatías

Country Status (16)

Country Link
US (2) US20180036295A1 (es)
EP (2) EP3267983B1 (es)
JP (2) JP6990110B2 (es)
KR (1) KR20170123329A (es)
CN (1) CN107872976A (es)
AU (1) AU2016229826A1 (es)
CA (1) CA2978883A1 (es)
EA (1) EA201791993A1 (es)
ES (1) ES2973101T3 (es)
HK (1) HK1244217A1 (es)
IL (1) IL254393A0 (es)
MX (1) MX2017011598A (es)
PL (1) PL3267983T3 (es)
PT (1) PT3267983T (es)
TW (1) TW201642855A (es)
WO (1) WO2016145046A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018234864A2 (en) * 2017-06-19 2018-12-27 Kainos Medicine Inc. ALPHA-SYNUCLEINE MODULATORS
TWI644673B (zh) * 2017-07-27 2018-12-21 百朗克股份有限公司 頭孢曲松的用途
JP2022519131A (ja) * 2019-02-04 2022-03-18 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
CN113645969A (zh) * 2019-02-04 2021-11-12 建新公司 用于治疗与溶酶体贮积症相关的症状和病症的方法
BR112022014553A2 (pt) * 2020-02-03 2022-09-20 Genzyme Corp Métodos para tratamento de sintomas neurológicos associados a doenças do armazenamento lisossômic
JPWO2021187486A1 (es) 2020-03-17 2021-09-23
JP2023518838A (ja) * 2020-03-23 2023-05-08 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｋｃｎｔ１阻害剤及び使用方法
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.
BR112023001362A2 (pt) 2020-07-30 2023-02-14 Genzyme Corp Métodos para redução da concentração de glicoesfingolipídio no tecido cerebral e métodos de tratamento doenças neurodegenerativas envolvendo os mesmos
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
WO2024116127A1 (en) 2022-12-01 2024-06-06 Genzyme Corporation Venglustat in combination with a strong or moderate inhibitor of cyp3a4

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683A (en) 1846-08-08 waring and richard e
US195A (en) 1837-05-15 Machine fob cutting and dressing stone
BE640616A (es) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
MX365245B (es) * 2011-03-18 2019-05-28 Genzyme Corp Inhibidores de glucosilceramida sintasa.
JP6061922B2 (ja) * 2011-06-22 2017-01-18 ザ ジェネラル ホスピタル コーポレイション プロテイノパチーの処置方法
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
IL254393A0 (en) 2017-11-30
JP6990110B2 (ja) 2022-02-10
MX2017011598A (es) 2017-12-20
AU2016229826A1 (en) 2017-10-26
JP2021119185A (ja) 2021-08-12
TW201642855A (zh) 2016-12-16
EP4349408A3 (en) 2024-06-19
US20180036295A1 (en) 2018-02-08
WO2016145046A1 (en) 2016-09-15
PL3267983T3 (pl) 2024-05-13
CN107872976A (zh) 2018-04-03
EP4349408A2 (en) 2024-04-10
EA201791993A1 (ru) 2017-12-29
US20200197374A1 (en) 2020-06-25
JP7374149B2 (ja) 2023-11-06
CA2978883A1 (en) 2016-09-15
EP3267983A1 (en) 2018-01-17
HK1244217A1 (zh) 2018-08-03
JP2018507886A (ja) 2018-03-22
PT3267983T (pt) 2024-03-12
KR20170123329A (ko) 2017-11-07
EP3267983B1 (en) 2023-12-20

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
ES2973101T3 (es) Métodos para tratar proteinopatías
DK3231444T3 (da) Ny behandling
CL2015002801A1 (es) Métodos para tratar la osteogénesis imperfecta.
DK3110442T3 (da) Modificerede meningokok-fhbp-polypeptider
DK3283210T3 (da) Fremgangsmåde
DK3296597T3 (da) Krydshovedmotor
BR112017002318A2 (pt) combinações de fármacos para tratar mieloma múltiplo.
DK3132009T3 (da) Fremgangsmåde
BR112016029236A2 (pt) métodos para tratar prurido.
ES1145159Y (es) Aparato para eliminar piojos.
BR112017027349A2 (pt) método para melhorar os benefícios de saúde
DK3285588T3 (da) Fremgangsmåde
ITUB20156002A1 (it) Composizione e metodo per trattare i nematodi
ES1110782Y (es) Aparato para hacer gimnasia
ES1135628Y (es) Monoboya para vertido controlado
DK3349722T3 (da) Topisk hirsutisme-behandling
ITUB20161250A1 (it) Metodo per disinfestare derrate
ES1138882Y (es) Maquina para conformar fardos
UA32276S (uk) Шкіра
TWD174591S (zh) 按摩器
TWD174592S (zh) 按摩器
FI20150082A (fi) Hoitoväline
ES1134780Y (es) Patinete
ES1133683Y (es) Calcetin para prevenir lesiones